Hutchison China Meditech Limited Blocklisting Six Monthly Return (7017L)

TIDMHCM

RNS Number : 7017L

Hutchison China Meditech Limited

31 December 2018

Blocklisting Six Monthly Return

London: Monday, December 31, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:

 
1.   Name of applicant:            Hutchison China MediTech Limited 
2.   Name of scheme:               (a)    Share Option Scheme conditionally adopted 
                                           by Hutchison China MediTech Limited 
                                           in 2005 ("2005 HCML Share Option Scheme") 
                                   (b)    Share Option Scheme conditionally adopted 
                                           by Hutchison China MediTech Limited 
                                           in 2015 ("2015 HCML Share Option Scheme") 
3.   Period of return:             From June 29, 2018 to December 28, 2018 
4.   Balance under scheme          (a)          2005 HCML Share Option Scheme: 219,353 
      from previous return:                      ordinary shares of US$1 each 
                                   (b)          2015 HCML Share Option Scheme: 2,425,597 
                                                 ordinary shares of US$1 each 
5.   The amount by which           (a)    2005 HCML Share Option Scheme: Nil 
      the block scheme has 
      been increased, if 
      the scheme has been 
      increased since the 
      date of the last return: 
                                   (b)    2015 HCML Share Option Scheme: Nil 
6.   Number of securities          (a)    2005 HCML Share Option Scheme: 12,562 
      issued/allotted under                ordinary shares of US$1 each 
      scheme during period: 
                                   (b)    2015 HCML Share Option Scheme: 112,500 
                                           ordinary shares of US$1 each 
7.   Balance under scheme          (a)    2005 HCML Share Option Scheme: 206,791 
      not yet issued/allotted              ordinary shares of US$1 each 
      at end of the period: 
                                   (b)    2015 HCML Share Option Scheme: 2,313,097 
                                           ordinary shares of US$1 each 
8.   Number and class of           (i)    2,560,606 ordinary shares of US$1 each 
      securities originally                admitted on June 26, 2007 
      listed and the date 
      of admission: 
                                   (ii)   1,000,000 ordinary shares of US$1 each 
                                           admitted on June 20, 2016 
                                   (iii)  1,425,597 ordinary shares of US$1 each 
                                           admitted on April 27, 2018 
9.   Total number of securities    66,657,745 ordinary shares of US$1 each 
      in issue at the end 
      of the period: 
Name of contact:                   Christian Hogg 
Address of contact:                Level 18, The Metropolis Tower, 10 Metropolis 
                                    Drive, Hung Hom, Kowloon, Hong Kong 
Telephone number of contact:       [phone] 
 

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 400 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President, 
   Corporate Finance & Development                               [phone] 
  David Dible, Citigate Dewe Rogerson                            [phone] (Mobile) 
                                                                 [e-mail] 
  Xuan Yang, Solebury Trout                                      [phone] (Mobile) 
                                                                  [e-mail] 
 
Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson         [phone] (Mobile) 
                                                                  [e-mail] 
  Americas - Brad Miles, Solebury Trout                          [phone] (Mobile) 
                                                                  [e-mail] 
  Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick           [phone] (Mobile) 
                                                                  [e-mail] 
                                                     Zhou Yi,    [phone] (Mobile) 
                                                     Brunswick    [e-mail] 
  Mainland China - Sam Shen, Edelman                             [phone] (Mobile) 
                                                                  [e-mail] 
 
Nominated Advisor 
  Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited       [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BLRUWSKRWBAUURA

(END) Dow Jones Newswires

December 31, 2018 02:00 ET (07:00 GMT)